Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated ...
Obsidian Therapeutics, Inc., a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today ...
Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable ...
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States ...
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study ...
The second phase of widening Interstate 81 in Washington County, Maryland, will be split into two parts to keep the project on schedule. Construction for Phase 2A is expected to begin in 2027, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results